96 Tests PN: B136519

Components:

45x Ab-conjugated beads (S4P11 - Human ST2 Ab-bead). PN: B136519A. One vial containing 100 µL of anti-Human ST2 conjugated to AimPlex Bead S4P11.

25x Biotin-detection (ST2 Biotin-dAb). PN: B136519B. One vial containing 100 µL of biotinylated anti-Human ST2.

Lyophilized Standard Mix-Human Group 8, Panel B, 11-Plex. PN: HG82011. One vial containing lyophilized recombinant Cystatin C, FGF-1, FGF-19, Flt-3L, GDF-15, Granzyme B, NGAL, PAPP-A, SLPI, RAGE, and ST2. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Human ST2/IL-1 R4/IL-1RL1. Can be multiplexed with other analytes in Human Group 8.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 2 pg/mL

  • Quantitation range:

  • LLOQ: < 5 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 8: Negligible

  • Sample volume: 15 µL/test

Description:

ST2, also known as IL-1R4 and IL-33R, is a transmembrane glycoprotein in the interleukin-1 receptor family. ST2 is expressed on mast cells and Th2 cells as well as on stressed cardiac myocytes and airway epithelia. ST2 associates with IL-1R AcP to form a receptor complex for IL-33. Alternative splicing generates ST2, a secreted isoform that functions as an inhibitor of IL-33 signaling. The ST2 cardiac biomarker is a novel biomarker of cardiac stress. ST2 signals the presence and severity of adverse cardiac remodeling and tissue fibrosis, which occurs in response to myocardial infarction, acute coronary syndrome, or worsening heart failure. ST2 is a strong predictor of cardiovascular death and risk of developing new heart failure in ST Elevation Myocardial Infarction (STEMI) & NSTE-ACS patients. In patients presenting with Acute Coronary Syndrome, those in the highest quartile (>35 ng/ml) have more than 3 times higher risk of cardiovascular death and new heart failure at 30 days, than those in the lower quartiles. At one year, there is a relative risk of 2.3 for adverse outcomes.

References:

  1. Shah RV, Januzzi JL (March 2010). "ST2: a novel remodeling biomarker in acute and chronic heart failure". Curr Heart Fail Rep 7 (1): 9–14. doi:10.1007/s11897-010-0005-9. PMID 20425491.

  2. Rehman SU, Mueller T, Januzzi JL (October 2008). "Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure". J. Am. Coll. Cardiol. 52 (18): 1458–65. doi:10.1016/j.jacc.2008.07.042. PMID 19017513.

  3. Braunwald E (May 2008). "Biomarkers in heart failure". N. Engl. J. Med. 358 (20): 2148–59. doi:10.1056/NEJMra0800239. PMID 18480207.

  4. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP (March 2011). "High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure". Circ Heart Fail 4 (2): 180–7. doi:10.1161/CIRCHEARTFAILURE.110.958223. PMC 3163169. PMID 21178018.P Kohli. "Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial". Clinical Chemistry.